Compile Data Set for Download or QSAR
Report error Found 192 Enz. Inhib. hit(s) with all data for entry = 10446
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359614(N-[(1-Aminoisoquinolin-6-yl)methyl]-({4-[(4-methyl...)
Affinity DataIC50: 3.86nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM535979(N-{[4-(Aminomethyl)-2,6-dimethylphenyl]methyl}-5-(...)
Affinity DataIC50: 7.47nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM535978(N-{[4-(Aminomethyl)-2-methylphenyl]methyl}-5-({4-[...)
Affinity DataIC50: 14.4nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359648(N-[(1-Aminoisoquinolin-6-yl)methyl]-5-({3-methoxy-...)
Affinity DataIC50: 17.1nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359618(N-[(1-Aminoisoquinolin-6-yl)methyl]-6-oxo-1-({4-[(...)
Affinity DataIC50: 24.7nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359631(N-[(1-Aminoisoquinolin-6-yl)methyl]-5-[(2-methylqu...)
Affinity DataIC50: 27.5nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359623(N-[(1-Aminoisoquinolin-6-yl)methyl]-6-({4-[(4-meth...)
Affinity DataIC50: 30.8nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359621(N-((1-Aminoisoquinolin-6-yl)methyl)-5-(hydroxy(4-(...)
Affinity DataIC50: 35.3nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359695(US10221161, Example 77 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 37.7nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359689(US10221161, Example 73 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 51.1nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM535951(N-[(1-Aminoisoquinolin-6-yl)methyl]-5-{[6-(diethyl...)
Affinity DataIC50: 52.7nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM535906(N-[(1-Aminoisoquinolin-6-yl)methyl]-6-(methylamino...)
Affinity DataIC50: 53.3nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359713(N-{[4-(Aminomethyl)-2,6-dimethylphenyl]methyl}-6-(...)
Affinity DataIC50: 53.6nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359700(US10221161, Example 82 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 67.8nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359682(US10221161, Example 67 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 73.3nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359625(N-[(1-Aminoisoquinolin-6-yl)methyl]-5-({4-[(4-meth...)
Affinity DataIC50: 82.3nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359692(US10221161, Example 74 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 83.1nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359698(US10221161, Example 80 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 88.5nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359670(US10221161, Example 55 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 103nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM535907(N-[(1-Aminoisoquinolin-6-yl)methyl]-2-methyl-5-[(2...)
Affinity DataIC50: 104nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359707(N-[(1-Aminoisoquinolin-6-yl)methyl]-5-({2-[2-(hydr...)
Affinity DataIC50: 104nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359701(US10221161, Example 83 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 106nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359653(N-[(1-Aminoisoquinolin-6-yl)methyl]-5-[(4-methyl-2...)
Affinity DataIC50: 107nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359622(N-[(1-Aminoisoquinolin-6-yl)methyl]-6-({4-[(4-meth...)
Affinity DataIC50: 119nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359655(N-[(1-Aminoisoquinolin-6-yl)methyl]-5-{[2-(4-methy...)
Affinity DataIC50: 127nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359680(US10221161, Example 65 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 131nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359675(US10221161, Example 60 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 137nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359676(US10221161, Example 61 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 137nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359646(N-[(1-Aminoisoquinolin-6-yl)methyl]-5-(quinolin-6-...)
Affinity DataIC50: 144nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359673(US10221161, Example 58 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 153nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359697(US10221161, Example 79 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 155nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359616(N-[(1-Aminoisoquinolin-6-yl)methyl]-4-({4-[(4-meth...)
Affinity DataIC50: 159nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359629(N-[(1-Aminoisoquinolin-6-yl)methyl]-1-({4-[(4-meth...)
Affinity DataIC50: 159nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359696(US10221161, Example 78 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 164nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359630(N-[(1-Aminoisoquinolin-6-yl)methyl]-1-[(2-methylqu...)
Affinity DataIC50: 179nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359624(N-[(1-Aminoisoquinolin-6-yl)methyl]-6-[(2-methylqu...)
Affinity DataIC50: 194nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359668(US10221161, Example 53 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 200nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359615(5-({4-[(4-Methylpyrazol-1-yl)methyl]phenyl}methyl)...)
Affinity DataIC50: 216nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359706(US10221161, Example 88 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 234nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetKallikrein-1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM535898(N-({2,4-Dimethyl-7H-pyrrolo[2,3-b]pyridin-3-yl}met...)
Affinity DataIC50: 236nMAssay Description:KLK1 inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359647(N-[(1-Aminoisoquinolin-6-yl)methyl]-5-{[3-(pyrazol...)
Affinity DataIC50: 237nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359672(US10221161, Example 57 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 240nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359694(US10221161, Example 76 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 242nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM535897(N-({2,4-Dimethyl-7H-pyrrolo[2,3-b]pyridin-3-yl}met...)
Affinity DataIC50: 244nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359677(US10221161, Example 62 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 255nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359645(N-[(1-Aminoisoquinolin-6-yl)methyl]-5-{[3-(pyrazol...)
Affinity DataIC50: 302nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359687(US10221161, Example 71 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 306nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359671(US10221161, Example 56 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 313nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359706(US10221161, Example 88 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 355nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM359705(US10221161, Example 87 | N-[(1-Aminoisoquinolin-6-...)
Affinity DataIC50: 358nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Displayed 1 to 50 (of 192 total ) | Next | Last >>
Jump to: